Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Pain, Cannabis Species, and Cannabis Use Disorders.

Cohen NL, Heinz AJ, Ilgen M, Bonn-Miller MO.

J Stud Alcohol Drugs. 2016 May;77(3):515-20.

PMID:
27172585
2.

Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.

de Vries M, Van Rijckevorsel DC, Vissers KC, Wilder-Smith OH, Van Goor H.

Br J Clin Pharmacol. 2016 Mar;81(3):525-37. doi: 10.1111/bcp.12811. Epub 2016 Jan 17.

PMID:
26505163
3.

Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

McPartland JM, Duncan M, Di Marzo V, Pertwee RG.

Br J Pharmacol. 2015 Feb;172(3):737-53. doi: 10.1111/bph.12944. Review.

4.

Medical marijuana: A panacea or scourge.

Kashyap S, Kashyap K.

Lung India. 2014 Apr;31(2):145-8. doi: 10.4103/0970-2113.129843. Review.

5.

Mechanisms and pharmacology of neuropathic pain in multiple sclerosis.

Iannitti T, Kerr BJ, Taylor BK.

Curr Top Behav Neurosci. 2014;20:75-97. doi: 10.1007/7854_2014_288.

6.

Cannabidiol in humans-the quest for therapeutic targets.

Zhornitsky S, Potvin S.

Pharmaceuticals (Basel). 2012 May 21;5(5):529-52. doi: 10.3390/ph5050529.

7.

The endocannabinoid system, cannabinoids, and pain.

Fine PG, Rosenfeld MJ.

Rambam Maimonides Med J. 2013 Oct 29;4(4):e0022. doi: 10.5041/RMMJ.10129. eCollection 2013.

8.

The therapeutic potential of cannabis and cannabinoids.

Grotenhermen F, Müller-Vahl K.

Dtsch Arztebl Int. 2012 Jul;109(29-30):495-501. Epub 2012 Jul 23. Review.

9.

The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?

Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ.

Per Med. 2011 Mar;8(2):161-173.

10.

Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.

Lynch ME, Campbell F.

Br J Clin Pharmacol. 2011 Nov;72(5):735-44. doi: 10.1111/j.1365-2125.2011.03970.x. Review.

11.

The analgesic potential of cannabinoids.

Elikkottil J, Gupta P, Gupta K.

J Opioid Manag. 2009 Nov-Dec;5(6):341-57. Review. Erratum in: J Opioid Manag. 2010 Jan-Feb;6(1):14. Elikottil, Jaseena [corrected to Elikkottil, Jaseena].

12.

Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.

Rahn EJ, Hohmann AG.

Neurotherapeutics. 2009 Oct;6(4):713-37. doi: 10.1016/j.nurt.2009.08.002. Review.

13.

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.

Ware MA, Daeninck P, Maida V.

Ther Clin Risk Manag. 2008 Feb;4(1):99-107.

14.

Cannabinoids in the management of difficult to treat pain.

Russo EB.

Ther Clin Risk Manag. 2008 Feb;4(1):245-59.

15.
16.

Cannabinoids in health and disease.

Kogan NM, Mechoulam R.

Dialogues Clin Neurosci. 2007;9(4):413-30. Review.

17.

Cannabinoids for chronic pain.

Cohen SP.

BMJ. 2008 Jan 26;336(7637):167-8. doi: 10.1136/bmj.39434.444583.80. Epub 2008 Jan 8. No abstract available.

20.

The endocannabinoid system as an emerging target of pharmacotherapy.

Pacher P, Bátkai S, Kunos G.

Pharmacol Rev. 2006 Sep;58(3):389-462. Review.

Items per page

Supplemental Content

Write to the Help Desk